Previa Medical, a provider of an EHR-integrated intelligence software platform that enables clinicians to diagnose and classify life-threatening sepsis infections and offers immediate treatment options, raised €2.1 million in seed funding.
French investment bank Bpifrance led the investment round with participation from BNP Paribas, CCI Capital Croissance, Hopla Memory, Veymont Participations, M2care, and Holding Seraip. Banque populaire AURA also participated in the round, providing a mix of equity capital and loans.
With the new investment, the startup intends to further develop and commercialize its sophisticated software solution that enables medical professionals to predict the onset of sepsis. Sepsis refers to the body’s most drastic biological response to an infection. While any bacterial infection left unchecked can cause sepsis, it is a grave emergency with risk to life as the body’s immune system damages critical organs and tissues.
According to our database, clinical intelligence and clinical decision software solutions providers have raised close to $15 billion in funding.
The latest funding rounds in clinical intelligence include:
Pearl Health, a provider of a data-driven clinical decision-making support platform for value-based care primary care providers, raised $75 million in Series B funding.
Fountain Life, an AI-powered precision diagnostics solution for care providers to detect cancer, heart disease, and dementia in their earliest stages, received $15 million in funding from Eos Venture Partners and Newcross Healthcare.
Onc.ai, a provider of an AI-powered physician-centered cancer care support platform for oncologists, recently announced the closing of its $25 million Series A funding round.
Ibex Medical Analytics, a provider of AI-guided cancer diagnostic solutions for pathologists, raised $10 million in debt funding from Kreos Capital, a growth debt capital provider for startups.
Volta Medical – a provider of artificial intelligence solutions that assist electrophysiologist physicians in treating complex cardiac arrhythmias such as atrial fibrillation (AF) – raised €36 million in new Series B funding.